RÉSUMÉ
Objective The present report describes the clinical effects of parental haploidentical hematopoietic stem cell transplantation (hi-allo-HSCT) in the treatment of hematologic diseases. Methods A total of 45 patients received parental hiallo- HSCT from July 2007 to January 2011. The therapeutic effects and complications were observed. Results Engraftment was successful in a total of 43 patients. Implantation failed in 2 patients. The incidence of the graft versus host disease (GVHD) was 62.2%. The incidence of acute GVHD was 40.0%, and chronic GVHD occurred in 22.2% of the patients. The incidence of GVHD was lower when the father was the donor compared with the mother was the donor. The incidence of GVHD was related to the age of the donor and the number of HLA matching sites. In addition, infections observed in the present study were mainly blood-borne with cytomegalovirus as the invader and lung infections. During the follow-up period of 6 months to 4 years, six patients died in the 43 patients with successful implantation. The major cause of death was infection and a relapse of their original disease. The disease free survival (DFS) rate was 86.7%. Seven patients additionally received umbilical cord blood, their efficacy in the transplantation seemed better than those who received parental stem cells only, as hematopoietic reconstruction was faster and the incidence of GVHD accounted for only 7.14% of the total incidence rate. Conclusions Parental hi-allo-HSCT is an effective treatment for hematologic diseases. A young male donor with more HLA matching sites is recommended to prevent GVHD and infection. The combination of parental hi-allo-HSCT and umbilical cord blood transplantation could result in positive effects with faster hematopoietic reconstruction and a lower incidence of GVHD.
RÉSUMÉ
<p><b>OBJECTIVE</b>To sum up the clinical experience of the diagnosis and treatment of intracerebral infiltration by monoclonal plasmacytoid cells in Waldenstrom's macroglobulinemia(Bing-Neel syndrome).</p><p><b>METHODS</b>The clinical data of the diagnosis and treatment of a case of Bing-Neel syndrome was analyzed.</p><p><b>RESULTS</b>A 56-year-old male was diagnosed as Waldenstrom's macroglobulinemia one year ago, and presented with persistent headache during the treatment period. Magnetic resonance imaging showed a high intensity area on T2-weighed images in the right frontal lobe which was well enhanced by gadolinium-diethylenetriaminepenta-acetic acid. Infiltration of neoplastic cells was confirmed by biopsy. Immunohistochemical examination showed that mature plasmacytoid cells in the cerebral parenchyma were immunoglobulin M positive.</p><p><b>CONCLUSION</b>Infiltration in CNS (Bing-Neel syndrome) is uncommon in Waldenstrom's macroglobulinemia. As there is no effective therapy for this Bing-Neel syndrome, combination of radiation and chemotherapy should be considered for this situation.</p>
Sujet(s)
Humains , Mâle , Adulte d'âge moyen , Encéphale , Anatomopathologie , Invasion tumorale , Macroglobulinémie de Waldenström , AnatomopathologieRÉSUMÉ
<p><b>OBJECTIVE</b>To study the inhibitory effect of zoledronic acid (ZA) on the growth and CD138 expression of myeloma cell line KM3.</p><p><b>METHODS</b>KM3 cells were treated with different concentrations of ZA The growth of KM3 cells was measured by trypan blue dye exclusion, and the changes of apoptosis rate, cell cycle and expression of CD138 induced by ZA by flow cytometry.</p><p><b>RESULTS</b>Within the concentration of 10(-5)-10(-3) mol/L, ZA obviously inhibited the growth of KM3 cells in a dose dependent manner. IBN at 10(-5)-10(-4) moL/L increased Annexin V positive rate, blocked cells at the S/G2 boundary, reduced the expression of CD138 and its fluorescence intensity.</p><p><b>CONCLUSION</b>ZA can inhibit the growth of KM3 cells in a dose-dependent manner and inhibited CD138 expression. The mechanism is probably related to induction cell cycle accumulation in S phase and apoptosis.</p>